Selective action of fluoroquinolones against intracellular amastigotes of Leishmania (Viannia) panamensis in vitro

Journal of Parasitology

Volumn 91, Issue 6, 2005, Pages 1474-1479

  Romero, Ibeth C ^a   Saravia, Nancy G ^a   Walker, John ^a  

^a CENTRO INTERNACIONAL DE ENTRENAMIENTO E INVESTIGACIONES MÉDICAS CIDEIM   (Colombia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARASITIC AGENT; CINOXACIN; CIPROFLOXACIN; CYCLOPROPANE DERIVATIVE; CYTOTOXIC AGENT; ENOXACIN; ENROFLOXACIN; GYRASE INHIBITOR; LOMEFLOXACIN; MILTEFOSINE; NALIDIXIC ACID; NICOTINIC ACID; NORFLOXACIN; OFLOXACIN; PEFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

PARASITOLOGY;

AMASTIGOTE; ANIMAL CELL; ANTIMICROBIAL ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG CYTOTOXICITY; DRUG POTENCY; DRUG SELECTIVITY; DRUG SENSITIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR TRANSPORT; LEISHMANIA PANAMENSIS; LINEAR REGRESSION ANALYSIS; MACROPHAGE ACTIVATION; NONHUMAN; REPORTER GENE;

ANIMALS; CELL LINE; CINOXACIN; CIPROFLOXACIN; ENOXACIN; FLUOROQUINOLONES; HUMANS; LEISHMANIA GUYANENSIS; MACROPHAGES; NALIDIXIC ACID; NORFLOXACIN; OFLOXACIN; QUINOLONES;

ANIMALIA; LEISHMANIA PANAMENSIS;

EID: 29144474202     PISSN: 00223395     EISSN: None     Source Type: Journal    
DOI: 10.1645/GE-3489.1     Document Type: Article

References (38)

1. ATCHINSON, J., AND S. D. SILVEY. 1957. The generalization of probit analysis to the case of multiple responses. Biometrika 44: 131-140.
2. BETBEDER, D., D. W. HUTCHISON, T. BALTZ, AND S. CROS. 1988. Trypanocidal and antitumor activities of nalidixic and oxolinic acid derivatives. Medical Science Research 16: 141-142.
3. BIANCHINI, V., AND S. D'AMICO. 2004. Use of the association of enrofloxacin (Baytril®) and metronidazole in the cure of leishmaniosis in dogs. Available at: http://www.leishmania.org.index.asp.
4. BIANCIARDI, P., A. FASANELLA, V. FOGLIA MANZILLO, T. TROTTA, A. PAGANO, S. SORINO, L. GRADONI, AND G. OLIVA. 2004. The efficacy of enrofloxacin, alone or combined with metronidazole, in the therapy of canine leishmaniasis. Parasitology Research 93: 486-492.
5. BODLEY, A. L., M. W. MCGARRY, AND T. S. SHAPIRO. 1995. Drug cytotoxicity assay for African trypanosomes and Leishmania species. Journal of Infectious Diseases 172: 1157-1159.
6. BOSQUE, F., G. MILON, L. VALDERRAMA, AND N. G. SARAVIA 1998. Permissiveness of human monocytes and monocyte-derived macrophages to infection of promastigotes of Leishmania (Viannia) panamensis. Journal of Parasitology 84: 1250-1256.
7. BURRI, C., A. L. BODLEY, AND T. A. SHAPIRO. 1996. Topoisomerases in kinetoplastids. Parasitology Today 12: 226-231.
8. CARLIER, M. B., B. SCORNEAUX, A. ZENEBERGH, J. F. DESNOTTES, AND P. M. TULKENS. 1990. Cellular uptake, localization and activity of fluoroquinolones in uninfected and infected macrophages. Journal of Antimicrobial Chemotherapy 26(suppl B): 27-39.
9. CHEESMAN, S. J. 2000. The topoisomerases of protozoan parasites. Parasitology Today 16: 277-281.
10. CROFT, S. L., AND J. HOGG. 1988. Limited activity of bacterial topoisomerase inhibitors against Leishmania donovani and Trypanosoma cruzi amastigotes in vitro. Transactions of the Royal Society for Tropical Medicine and Hygiene 82: 856.
11. DAS, A., A. DASGUPTA, S. SHARMA, M. GHOSH, T. SENGUPTA, S. BANDOPADHYAY, AND H. MAJUMDER. 2001. Characterization of the gene encoding type 11 DNA topoisomerase from Leishmania donovani: A key molecular target in antileishmanial therapy. Nucleic Acids Research 29: 1844-1851.
12. DESJEUX, P. 2001. The increase in risk factors for leishmaniasis world-wide. Transactions of the Royal Society for Tropical Medicine and Hygiene 95: 239-243.
13. DRLICA, K., AND X. ZHAO. 1997. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiology and Molecular Biology Reviews 61: 377-392.
14. FARAUT-GAMBARELLI, F., R. PIARROUX, M. DENIAU, B. GIUSIANO, P. MARTY, G. MICHEL, B. FAUGERE, AND H. DUMON. 1997. In vitro and in vivo resistance of Leishmania infantum to meglumine antimoniate: A study of 37 strains collected from patients with visceral leishmaniasis. Antimicrobial Agents and Chemotherapy 41: 827-830.
15. GONZALES-PERDOMO, M., S. LISBOA DE CASTRO, M. N. S. L. MEIRELLES, AND S. GOLDENBERG. 1990. Trypanosoma cruzi proliferation and differentiation are blocked by topoisomerase II inhibitors. Antimicrobial Agents and Chemotherapy 34: 1707-1714.
16. HERWALDT, B. L. 1999. Leishmaniasis. Lancet 354: 1191-1199.
17. HOOPER, D. C. 1998. Clinical applications of quinolones. Biochimica et Biophysica Acta 1400: 45-61.
18. JHA, T. K., S. SUNDAR, C. P. THAKUR, P. BACHMANN, J. KARBWANG, C. FISCHER, A. VOSS, AND J. BERMAN. 1999. Miltefosine, an oral agent for the treatment of Indian visceral leishmaniasis. New England Journal of Medicine 341: 1795-1800.
19. KEISER, J., AND C. BURRI. 2001. Evaluation of quinolone derivatives for antitrypanosomal activity. Tropical Medicine and International Health 6: 369-389.
20. LIU, L. F. 1989. DNA topoisomerase poisons as antitumor drugs. Annual Review of Biochemistry 58: 351-375.
21. MARQUIS, J-F., D. MAKHEY, E. J. LAVOLE, AND M. OLIVIER. 2003. Effects of topoisomerases inhibitors protoberberine on Leishmania donovani growth, macrophage function and infection. Journal of Parasitology 89: 1040-1052.
22. MARTINEZ S., S. GONZALES, AND M. E. VERNAZA. 1997. Treatment of cutaneous leishmaniasis with allopurinol and stibogluconate. Clinical Infectious Diseases 24: 165-169.
23. MORAIS-CABRAL, J. H., A. P. JACKSON, C. V. SMITH, N. SHIKOTRA, A. MAXWELL, AND R. C. LIDDINGTON. 1997. Crystal structure of the breakage-reunion domain of DNA gyrase. Nature 388: 903-906.
24. MORRISSEY, I., AND J. GEORGE. 1999. Activities of fluoroquinolones against Streptococcus pneumoniae type II topoisomerases purified as recombinant proteins. Antimicrobial Agents and Chemotherapy 43: 2579-2585.
25. NENORTAS, E., C. BURRI, AND T. A. SHAPIRO. 1999. Antitrypanosomal activity of fluoroquinolones. Antimicrobial Agents and Chemotherapy 43: 2066-2068.
26. -, KULIKOWICZ T., C. BURRI, AND T. A. SHAPIRO. 2003. Antitrypanosomal activities of fluoroquinolones with pyrrolidinyl substitutions. Antimicrobial Agents and Chemotherapy 47: 3015-3017.
27. PALACIOS R., L. E. OSORIO, L. F. GRAJALES, AND M. T. OCHOA. 2001. Treatment failure in children in a randomized clinical trial with 10 and 20 days of meglumine antimoniate for cutaneous leishmaniasis due to Leishmania Viannia species. American Journal of Tropical Medicine and Hygiene 64: 187-193.
28. PHYSICIANS' DESK REFERENCE®. 2004. 2nd ed. Thomson Healthcare Inc., Montvale, New Jersey, p. 254.
29. RAETHER, W. H., H. SEIDENATH, AND J. HOFMANN. 1989. Potent antibacterial fluoroquinolones with marked activity against Leishmania donovani in vivo. Parasitology Research 75: 412-413.
30. ROY, G., C. DUMAS, D. SERENO, Y. WU, A. K. SINGH, M. J. TREMBLAY, M. OUELLETTE, M. OLIVIER, AND B. PAPADOPOULOU. 2000. Episomal and stable expression of the luciferase reporter gene for quantifying Leishmania spp. infections in macrophages and in animal models. Molecular and Biochemical Parasitology 110: 195-206.
31. SAVOIA, D., S. BIGLINO, A. CESTARO, AND M. ZUCCA. 1993. In vitro and in vivo activity of some fluoroquinolones on two Leishmania species. European Bulletin of Drug Research 2: 135-138.
32. SOTO, J., B. A. ARANA, J. TOLEDO, N. RIZZO, J. C. VEGA, A. DIAZ, M. LUZ, P. GUTIERREZ, M. ARBOLEDA, J. D. BERMAN, K. JUNGE, J. ENGEL, AND H. SINDERMANN. 2004. Miltefosine for new world cutaneous leishmaniasis. Clinical Infectious Disease 38: 1266-72.
33. SUNDAR, S. 2001. Drug resistance in Indian visceral leishmaniasis. Tropical Medicine and International Health 6: 849-854.
34. TAKEI, M., H. FUKUDA, T. YASUE, M. HOSAKA, AND Y. OOMORI. 1998. Inhibitory activities of gatifloxacin (AM-1155), a newly developed fluoroquinolone, against bacterial and mammalian type II topoisomerases. Antimicrobial Agents and Chemotherapy 42: 2678-2681.
35. VELEZ, I., S. AGUDELO, E. HENDRICKX, J. PUERTA, M. GROGL, F. MODABBER, AND J. BERMAN. 1997. Inefficacy of allopurinol as monotherapy for Colombian cutaneous leishmaniasis: A randomized, controlled trial. Annals of Internal Medicine. 26: 232-236.
36. VILLA, H., A. R. OTERO-MARCOS, R. M. REGUERA, R. BALANA-FOUCE, C. GARCIA-ESTRADA, Y. PEREZ PERTEJO, B. L. TEKWANI, P. J. MYLER, K. D. STUART, M.-A. BJORNSTI, AND D. ORDONEZ. 2003. A novel active DNA topoisomerase I in Leishmania donovani. Journal of Biological Chemistry 278: 3521-3526.
37. WALKER, J., AND N. G. SARAVIA. 2004. Inhibition of Leishmania donovani promastigote DNA topoisomerase I and human monocyte DNA topoisomerases I and II by antimonial drugs and classical anti-topoisomerase agents. Journal of Parasitology 90: 1155-1162.
38. ZUCCA, M., M. MILLESIMO, M. GIOVARELLI, D. DIVERIO, T. MUSSO, AND D. SAVOIA. 1996. Protective role of the pefloxacin-IFN-gamma association in Leishmania major-infected mice. New Microbiology 19: 39-46.